A New Era in Oncology

NuCana is a clinical-stage biopharmaceutical company focused on significantly improving survival outcomes for patients with cancer. We use our proprietary ProTide™ technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines.

Our highly experienced management team has a successful track record of building global, integrated biopharmaceutical companies and bringing life-saving oncology therapeutics to patients.

STEP UP FOR
30

UK - "Bowel Cancer UK asks you to get sponsored for 30 minutes exercise for 30 days in June." - Bowel Cancer UK

Bowel Cancer Awareness Month

June 2018

June is Bowel cancer awareness month in the UK and Australia

Bowel Cancer Australia Red Apple Day Logo

Australia - "Raise awareness of Australia's second deadliest cancer throughout the month of June (1-30), including Red Apple Day on the 20th June 2018. Australians are encouraged to support bowel cancer awareness with apple themed fundraising activities." - Bowel Cancer Australia

Our Values

MISSION: To Transform Chemotherapy and Pioneer a New Era in Oncology

"Utilising our proprietary ProTide technology platform we are developing new medicines designed to overcome key cancer resistance mechanisms and improve the survival outcomes for patients."

Hugh S. Griffith

Founder & CEO
Hugh Griffith

PROTIDE
ACELARIN

Our lead product candidate is designed to overcome the key cancer resistance mechanisms associated with gemcitabine. Currently in Phase I, II and III studies.

PROTIDE
NUC-3373

Our second ProTide is designed to overcome the key cancer resistance mechanisms associated with 5-FU. Currently in a Phase I study in patients with advanced solid tumours.

PROTIDE
NUC-7738

A ProTide transformation of cordycepin, a novel nucleoside analog with a unique mode of action and potent anti-cancer activity in preclinical studies. Initiating a Phase I study in 2018.

NEW GENERATION
ANTI-CANCER AGENTS

NuCana's ProTide technology is a powerful platform generating new anti-cancer medicines designed to overcome the key cancer resistance mechanisms.

NUCANA'S
PIPELINE

We take a scientifically driven approach to designing our ProTides to address some of the most significant unmet medical needs in oncology.

LATEST
NEWS

NuCana announces promising clinical data at ASCO GI on NUC-1031 (Acelarin®) as front-line treatment of advanced biliary tract cancer.

Leadership

Meet Our Executive Team

Hugh Griffith

Hugh Griffith

Chief Executive Officer

Christopher Wood

Christopher Wood

Chief Medical Officer

San Francisco

Don Munoz

Chief Financial Officer

Global Headquarters

3 Lochside Way
Edinburgh
EH12 9DT
United Kingdom

Telephone: +44 (0)131 357 1111

E-mail: info@nucana.com

U.S. Office

275 Grove Street
Newton, MA 02466

Telephone: +1 617 663 4821

E-mail:info@nucana.com

Contact us